Key Points
- Director David Matlin bought 33,333 shares at $6.50 each (a $216,664.50 trade), boosting his stake ~7.5% to 477,824 shares (worth about $3.11M), as disclosed in an SEC filing.
- Clene announced additional CNM‑Au8 biomarker data and secured an in‑person FDA Type C meeting later this quarter, a clinical/regulatory milestone that could act as a near‑term catalyst toward an NDA pathway.
- The company remains early‑stage with weak recent results (Q EPS -$0.85 vs. -$0.60 est., revenue $0.02M) and a ~$55M market cap, while analyst coverage is mixed but shows a consensus " Moderate Buy " with an average target of $32.60.
Clene Inc. (NASDAQ:CLNN - Get Free Report) Director David Matlin acquired 33,333 shares of Clene stock in a transaction that occurred on Tuesday, January 13th. The stock was acquired at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the purchase, the director owned 477,824 shares of the company's stock, valued at $3,105,856. The trade was a 7.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Clene Stock Down 1.5%
Shares of NASDAQ:CLNN opened at $5.10 on Wednesday. The firm has a market cap of $55.34 million, a P/E ratio of -1.50 and a beta of 0.87. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The business has a fifty day simple moving average of $7.43 and a 200 day simple moving average of $6.46.
Clene (NASDAQ:CLNN - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, equities research analysts expect that Clene Inc. will post -5.19 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on CLNN. Benchmark reaffirmed a "buy" rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reaffirmed a "buy" rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a report on Friday. Finally, D. Boral Capital reissued a "buy" rating and issued a $23.00 price objective on shares of Clene in a research note on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Clene has a consensus rating of "Moderate Buy" and an average target price of $32.60.
View Our Latest Research Report on Clene
Hedge Funds Weigh In On Clene
Several institutional investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp bought a new position in shares of Clene during the 3rd quarter worth about $29,000. Jane Street Group LLC acquired a new position in Clene during the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. boosted its holdings in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock worth $199,000 after acquiring an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP grew its stake in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after acquiring an additional 42,750 shares during the period. Institutional investors and hedge funds own 23.28% of the company's stock.
Clene News Summary
Here are the key news stories impacting Clene this week:
- Positive Sentiment: Director David J. Matlin bought 33,333 shares at an average $6.50, increasing his stake by ~7.5% — a management buy that can signal confidence in the stock and upcoming catalysts. SEC Filing
- Positive Sentiment: Clene announced additional CNM‑Au8 biomarker data and that the FDA granted an in‑person Type C meeting later this quarter — a clinical/regulatory milestone that could support a potential NDA path and act as a near‑term catalyst if data or FDA feedback is favorable. GlobeNewswire Release
- Neutral Sentiment: Reported short interest data shows effectively zero shares and a 0.0 days‑to‑cover metric (the report contains anomalous/NaN values) — not currently a clear driver of pressure or squeeze risk. (Reported Jan 12)
- Neutral Sentiment: Analyst and institutional profile is mixed: multiple buy ratings and a high consensus price target sit against modest institutional ownership (~23%) and weak recent revenue/earnings — these set expectations but are not an immediate price trigger. MarketBeat Profile
- Negative Sentiment: Major shareholder Chidozie Ugwumba has executed a series of sales since late December (including 32,705 shares on Jan 12 and multiple smaller lots), reducing his position by several percent overall — sustained insider selling at recent prices can create downward pressure and prompt investor concern. InsiderTrades Report
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
